

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6610343

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT
EFFECTIVE DATE:	08/02/2018
CONVEYING PARTY DATA	
Name	Execution Date
JESSE JAYNES	03/15/2021
RECEIVING PARTY DATA	
Name:	NEXION BIOSCIENCES INC.
Street Address:	13155 NOEL ROAD, SUITE 900
City:	DALLAS
State/Country:	TEXAS
Postal Code:	75240
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	16134336
Application Number:	62764430
Application Number:	62764431
CORRESPONDENCE DATA	
Fax Number:	(214)866-0010
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2148660001
Email:	kthiesse@chalkerflores.com
Correspondent Name:	DANIEL CHALKER C/O CHALKER FLORES LLP
Address Line 1:	14951 NORTH DALLAS PARKWAY, SUITE 400
Address Line 4:	DALLAS, TEXAS 75254
ATTORNEY DOCKET NUMBER:	GENV:1001
NAME OF SUBMITTER:	KAREN THIESSE
SIGNATURE:	/KAREN THIESSE/
DATE SIGNED:	03/19/2021
Total Attachments: 1	
source=exGENV1001_Jaynes_Assignment_NuncProTunc--JJ#page1.tif	

PATENT ASSIGNMENT *NUNC PRO TUNC*

WHEREAS, Jesse Jaynes, having an address of 1583 Overhill Court, Auburn, Alabama 36830, is one of the inventors of the patent applications listed below;

WHEREAS, Jesse Jaynes agreed to assign the patent applications listed below to Nexion Biosciences Inc.;

WHEREAS, all property and enforcement rights in Nexion Biosciences Inc. have been assigned or otherwise transferred to Genvor Inc.;

WHEREAS, Jesse Jaynes has an ownership interest in Genvor Inc.; and

WHEREAS, Jesse Jaynes desires that Genvor Inc. own the patent applications listed below.

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, the undersigned, does hereby:


1. Sell, assign and transfer to Nexion Biosciences Inc., effective as of the respective filing dates below, any and all rights, title and interest in and to any and all inventions, subject matter and improvements disclosed in the patent applications listed below, any and all divisional, continuing, substitute, renewal, reissue or other applications for patent which have been or will be filed in any country based on the patent applications listed below, any and all original, reissued or reexamined patents which have been or will be issued in any country based on the patent applications listed below, and the right to file patent applications based on the patent applications listed below in any country:

U.S. Patent Application No. 62/764,430 and 62/764,431 filed on August 2, 2018, entitled "Designed Proteins for Improving the Nutritional Value of Food and Feed Crops" and "Designed Peptides with Potent Antimicrobial Activity"; and

U.S. Patent Application No. 16/134,336 filed on September 18, 2018 and entitled "Transgenic Corn with Antifungal Peptide AGM182 USDA (DN:0113.18).

2. In the event, the assignment or transfer of the patent applications listed above from Nexion Biosciences Inc to Genvor Inc. is ineffective, or the above assignment of the patent applications to Nexion Biosciences Inc is ineffective, the undersigned does hereby sell, assign and transfer to Genvor Inc., any and all rights, title and interest in and to any and all inventions, subject matter and improvements disclosed in the patent applications listed above, any and all divisional, continuing, substitute, renewal, reissue or other applications for patent which have been or will be filed in any country based on the patent applications listed above, any and all original, reissued or reexamined patents which have been or will be issued in any country based on the patent applications listed above, and the right to file patent applications based on the patent applications listed above in any country.

IN WITNESS WHEREOF, I have hereunto signed my name on the day and year set forth below.

Signature: 
Name: Jesse Jaynes
Date: March 15, 2021